Aquarius acquired by Matinas BioPharma after Matinas raised approximately $20M
Aquarius Biotechnologies participated in the tTAp partnering with three potential CEOs. In the tTAp process they were advised to focus on their lead compounds, and subsequently received an NIH grant to more their lead compound forward. They worked with one of them to develop and improve their messaging and presentation. Aquarius BioPharma’s lead compounds are now Matinas BioParmas’ lead compounds. See Aquarius in action at the tTAp
Using Cochleat Delivery Vehicles to develop oral formulations for IV and critical delivery formulations of existing pharmacologic agents, and to determine if the delivery is more effective than IV delivery. Amphoterician B, an antifungal, is their lead product in development.
- Technology Presenter: Rahael Mannino, President
- Oct Accelerator-Commercial Catalyst: Nick Gurreri, Formerly Sr. VP Insmed Inc.
- Nov Accelerator-Commercial Catalysts: Kevin J. Heyeck and Caroline Hoedemaker